Is Gilead Sciences (GILD) Stock Outpacing Its Medical Peers This Year?

Group 1 - Gilead Sciences (GILD) is outperforming the Medical sector with a year-to-date return of 27.1%, compared to the sector average gain of 6.8% [4] - Gilead Sciences holds a Zacks Rank of 2 (Buy), indicating strong analyst sentiment and an improving earnings outlook, with a 6.7% increase in the consensus earnings estimate for the full year [3] - The Medical - Biomedical and Genetics industry, which includes Gilead Sciences, has an average gain of 8% year-to-date, further highlighting GILD's strong performance [6] Group 2 - ANIXA BIOSCIENCES INC (ANIX) is another Medical stock that has outperformed the sector, with a year-to-date increase of 22.4% [4] - ANIXA BIOSCIENCES INC also holds a Zacks Rank of 2 (Buy), with a 10.9% increase in the consensus EPS estimate over the past three months [5] - Both Gilead Sciences and ANIXA BIOSCIENCES INC are expected to maintain their solid performance in the Medical sector [7]